Apheresis Procedure could Prevent Sequele of Hsv1 Encephalitis-Case Report

Slavic, Vjeroslava

doi:10.17352/aaa.000009

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Covered in the last review on blood apheresis technologies [22] Membrane with silicon dioxide nanoparticles Experimental Hemodialysis [23] Membrane with ferric oxide nanoparticles Experimental Hemodialysis [24] Membrane with multi-walled carbon nanotubes Experimental Hemodialysis [25] Membrane with graphene oxide nanoparticles Experimental Hemodialysis [26,27] Not covered in the last review on blood apheresis technologies [22] Membrane with nanoscale pores made of Lavsan film irradiated by accelerated in a collider charged argon particles Clinical TPE [9,[28][29][30][31][32][33]…”

Section: Type Of Nanotechnology Type Of Research Applications Referencesmentioning

confidence: 99%

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Tonev

Momchilova

2023

Biomedicines

View full text Add to dashboard Cite

Therapeutic plasma exchange (TPE) is an efficient extracorporeal blood purification technique to remove circulating autoantibodies and other pathogenic substances. Its mechanism of action in immune-mediated neurological disorders includes immediate intravascular reduction of autoantibody concentration, pulsed induction of antibody redistribution, and subsequent immunomodulatory changes. Conventional TPE with 1 to 1.5 total plasma volume (TPV) exchange is a well-established treatment in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis and Multiple Sclerosis. There is insufficient evidence for the efficacy of so-called low volume plasma exchange (LVPE) (<1 TPV exchange) implemented either by the conventional or by a novel nanomembrane-based TPE in these neurological conditions, including their impact on conductivity and neuroregenerative recovery. In this narrative review, we focus on the role of nanomembrane-based technology as an alternative LVPE treatment option in these neurological conditions. Nanomembrane-based technology is a promising type of TPE, which seems to share the basic advantages of the conventional one, but probably with fewer adverse effects. It could play a valuable role in patient management by ameliorating neurological symptoms, improving disability, and reducing oxidative stress in a cost-effective way. Further research is needed to identify which patients benefit most from this novel TPE technology.

show abstract

Section: Type Of Nanotechnology Type Of Research Applications Referencesmentioning

confidence: 99%

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Tonev

Momchilova

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…The nanomembrane is made of Lavsan film irradiated by accelerated charged argon particles in a collider, creating pores with diameters of 30-50 nm. This allows it to filter molecules with a weight of less than 40 kDa [21][22][23]. In nanomembrane-based LVPE, the most frequently used replacement fluid is saline solution, which has no side effects even when 25-30% of the circulated plasma is separated [24].…”

Section: Discussionmentioning

confidence: 99%

Nanomembrane-Based Apheresis: A Simple and Safe Procedure for Preventing Cardiovascular Complications in Metabolic Syndrome

Vjeroslava

2024

J PhyMed Rehab Stud Rep

View full text Add to dashboard Cite

Introduction: Metabolic syndrome (MetS) encompasses various abnormalities, including obesity, arterial hypertension, and diabetes, posing significant cardiovascular risks. Novel interventions are needed to address these risks promptly. This study evaluates the efficacy and safety of Nanomembrane-based low-volume plasma exchange (LVPE) in reducing cardiovascular risk factors in MetS patients. Material and Methods: Forty-eight MetS patients (31.3% female, 68.7% male, mean age 50 years) underwent four cycles of LVPE using the Hemofenix device and nanotech membrane PFM 500. LVPE, performed every other day, removed 30% of circulating plasma, replaced with saline. Blood samples were collected pre- and post-treatment for biomarker assessment. Results: LVPE significantly reduced systolic and diastolic blood pressure (p<0.001), sedimentation rate (p<0.0001), glucose (p<0.001), cholesterol (p<0.001), triglycerides (p<0.011), high-density lipoprotein cholesterol (p<0.006), fibrinogen (p<0.001), C-reactive protein (CRP) (p<0.02), and high-sensitivity CRP (p<0.06). No significant changes occurred in the complete blood count. Conclusions: LVPE emerges as a promising, minimally invasive intervention for reducing cardiovascular risk factors in MetS patients. By targeting proinflammatory and proatherogenic factors, LVPE could revolutionize MetS management and prevent cardiovascular complications. Future studies should optimize LVPE protocols and assess long-term efficacy in larger cohorts.

show abstract

“…Even more, American Society for Apheresis in 2013 approved this kind of procedure as minimally invasive and safe because it is performed on a single needle and removed plasma is replaced by saline solution [22]. According to the literature, apheresis procedure in combination with extracorporeal laser blood irradiation could be a highly effective therapeutic tool in the prevention of brain damage caused by HSV1 encephalitis [23].…”

Section: Discussionmentioning

confidence: 99%

Nanomembrane-based Apheresis as Safe and Effective Therapy for Cytomegalovirus and Epstein-Barr Virus Reactivation

Slavic¹,

Djurdjic²,

Randjelović³

et al. 2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Heavy training schedules or endurance competitions in marathon are forms of extreme physical stress and lead to immunodepression in runners which could be associated with increased susceptibility to viral reactivation by ubiquitous viral infection such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Lately, it was confirmed presence of elevated CMV and EBV loads and the lower antibody titers in competitive athletes. The most common clinical features are fatigue and adynamia accompanied with liver damage, varying from mild and transient elevation of aminotransferases to serious acute hepatitis and liver failure. CASE REPORT: Bearing in mind that a professional practice of marathon running is hazardous for the liver, therapeutic action is necessary as soon as possible to avoid serious complications and even cessation of professional competition. In our case report of professional female marathon runner, we need to treat CMV and EBV reactivation which caused liver damage, prevented regular trainings, and upcoming competitions. We opted for four sessions of nanomembrane based apheresis performed every other day for removal pathological products resulting from virus reactivation to break through the course of the disease and to prevent complications. After completing the whole procedure control laboratory tests and abdominal ultrasound were in physiological ranges. CONCLUSION: Hence, nanomembrane based apheresis can be effective and safe treatment of liver damages for elite marathon runners as well as for athletes.

show abstract

Apheresis Procedure could Prevent Sequele of Hsv1 Encephalitis-Case Report

Cited by 3 publications

References 19 publications

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology

Nanomembrane-Based Apheresis: A Simple and Safe Procedure for Preventing Cardiovascular Complications in Metabolic Syndrome

Nanomembrane-based Apheresis as Safe and Effective Therapy for Cytomegalovirus and Epstein-Barr Virus Reactivation

Contact Info

Product

Resources

About